

ICE Tools for Aligning Assay Endpoints to Adverse Outcome Pathways

SM Bell¹, LD Burgoon², J Phillips³, P Ceger¹, A Karmaus¹, D Allen¹, W Casey⁴, N Kleinstreuer⁴

¹ILS, RTP, NC, USA; ²U.S. Army Engineer Research and Development Center, Vicksburg, MS, USA; ³Sciome LLC, RTP, NC, USA; ⁴NIH/NIEHS/DNTP/NICEATM, RTP, NC, USA

Toward Non-animal Methods to Address Chemical Safety

Implementing non-animal approaches in regulatory toxicology testing poses challenges


The recent U.S. roadmap (<https://ntp.niehs.nih.gov/go/natl-strategy>) for establishing new approaches to evaluate the safety of chemicals and medical products described three challenges to implementing non-animal approaches:

- Understanding end-user needs
- Defining context of use for non-animal approaches
- Establishing confidence in these approaches




Adverse outcome pathways (AOPs) help address these challenges

- Adverse outcomes (AOs) relate to regulatory endpoints
- Key events (KEs) describe the critical biological interactions leading to the AO
- Assays and non-animal methods, including high throughput testing (HTT), can be developed targeting the KEs
- Assays relevant to the biology defined by the AOP can be integrated into defined approaches
- Tools and resources going from assay to KE are needed to help facilitate this process



AOPXplorer

- A plugin for the open source network visualization software Cytoscape (www.cytoscape.org) that allows visualization of users' data onto AOP networks (AOPNs)
- Enables overlaying of high-throughput screening and omics data onto AOPNs
- Supports mechanistic causal analysis
- Available at <http://apps.cytoscape.org/apps/aopxplorer>




AOPXplorer

Integrated Chemical Environment

The National Toxicology Program's Integrated Chemical Environment (ICE) is a data resource that includes:

- In vivo, in vitro, and in silico data from NICEATM and partners, curated and formatted to support exploration and use in computational workflows
- Reference chemical lists (for a given assay or endpoint) and associated data
- Computational tools and workflows



What can ICE do?

ICE supports:

- Data integration: bringing together data from different endpoints and experiments for comparison and exploration
- Results exploration: dynamic, graphical exploration of query results with capability to refine
- Data accession: obtaining reference chemical lists and supporting data
- Data analysis: downloadable computational tools and workflows to support test method assessment and development

Need for an Ontology

- Ontologies facilitate organization of information so it can be easily shared and reused by machines.
- An ontology incorporating biological context, assay context, and AOP information is necessary to link the data to the tools that work on different data types.
- BioAssay Ontology (BAO, <http://bioassayontology.org>) is a commonly used ontology to describe screening assays.
 - Does not include coverage for in vivo and low throughput assays
- AOP ontology describes key event relationships and is part of AOPXplorer.



ICE Ontology and AOP Mapping

ICE Ontology allows alignment of ICE assays with key events by:

- Adding ontological support for in vivo and low throughput assays
 - Extends BioAssay Ontology
- Complementing the AOP ontology and facilitating AOP mapping of ICE data
- Linking assays to toxicity endpoints used by regulators

Overlaying of ICE data onto AOPNs

The follow series of images give a high-level overview of how to go from ICE query to AOPXplorer network. Look for tutorials and within-ICE support coming soon.

The screenshot displays the 'Integrator' section of the Integrated Chemical Environment (ICE) web application. The interface includes a navigation menu at the top with 'Home', 'Integrator', 'Workflows', 'Reference Data', 'About', and 'Help'. The main content area is divided into several panels:


- Select Assays:** A panel on the left with a search bar and a 'Run Search' button. Below it, a list of assay categories is shown, including 'Acute Oral Toxicity', 'Skin Sensitization', 'Skin Irritation', 'Eye Irritation', 'Endocrine', 'Androgen', 'Estrogen', 'In vitro (all)', and 'In silico'. The 'Skin Sensitization' and 'In vitro (all)' categories are selected.
- Select Chemicals:** A panel at the bottom left with a search bar and a 'Select Reference Lists' button. It prompts the user to 'Enter one CASRN per line'.
- Download Table:** A table on the right showing the results of the search. It has columns for 'Substance Name', 'CASRN', and 'DPRA'. The table lists four substances: Glycerol, 5-Methyl-2,3-hexa..., Linalool, and Benzoyl peroxide.
- Bar Chart:** A bar chart titled 'Skin Sensitization' showing 'Cell Counts' for five assays: DPRA, hCLAT, Human Potency, KeratInoSens, and LLNA. The chart uses stacked bars with red and blue segments.

A callout box with a blue border and white background is overlaid on the right side of the interface. It contains the following text:

1. Run ICE Query
Search ICE for all data by endpoint for specific chemicals and let the integrator combine the data into a computational-friendly table

Substance Name	CASRN	DPRA
Glycerol	56-01-5	[0-1.6
5-Methyl-2,3-hexa...	13706-86-0	16.65
Linalool	78-70-6	[1.35
Benzoyl peroxide	94-36-0	90.65

Assay	Red Count	Blue Count	Total Count
DPRA	8	2	10
hCLAT	7	2	9
Human Potency	4	9	13
KeratInoSens	28	1	29
LLNA	2	7	9



```
1 |---
2 |title: "ICE to AOP Notebook"
3 |output: html_notebook
4 |---
5 |# ICE to AOP
6 |Author: Shannon M. Bell
7 |Affiliation: Integrated Laboratory
8 |Date: 8/20/2017
9 |
10 |## Introduction
11 |The [Integrated Chemical Environment] is a central access
12 |point to data relevant to chemical laboratory
13 |tests. Adverse outcome pathways (AOP) by events
14 |leading to some adverse outcome. Use data from
15 |ICE can be formatted for display in AOPXplorer (http://apps.cytoscape.org/).
16 |of [Cytoscape] (http://cytoscape.org/).
```

2. Prepare Data
Use the workflow to link the ICE data to Ontology and prepare it for AOPXplorer. Functionality will be online in ICE in the coming year

3. Choose the AOPN of Interest
In Cytoscape, under the AOPXplorer tab choose the AOPN of interest

id	parent name	name	id	type	NumChildren	NumDescendants
	activation of dendritic cells	activation...		action		
	covalent interaction with skin proteins	covalent in...		action		
	proliferation of activated T-cells	proliferatio...		action		
	inflammation upon challenge with irritants	inflammato...		action		
	keratinocyte inflammatory response	keratinocyt...		action		


4. Add ICE Data
Import your ICE query from step 2 using the "import table" feature.

Target Table Data
Where to Import Table Data: To a Network Collection
Select a Network Collection
Collection: skin_sensitization
Import Data as: Node Table Columns
Parent Network: shared name
Key Values:

Click on a column to edit it.

KE	*S-Methyl-	Linalool	Glycerol	Benz
covalent interaction with skin p...	1	-1	-1	
activation of dendritic cells	1	1	-1	
inflammation upon challenge wi...	1	-1	-1	
keratinocyte inflammatory res...	1	-1	-1	
proliferation of activated T-cells	1	1	-1	

Advanced Options...
OK Cancel




View a video with more detailed instructions on using AOPXplorer at <https://www.youtube.com/watch?v=vS3J6OuScQU>.

Case Studies

Exported ICE queries can be easily uploaded into Cytoscape for use with AOPXplorer. Below are case studies to illustrate questions one can ask with data from ICE (or other sources). The nodes along the AOPNs are KEs; the final KE is the AO.


What is the concordance of my data?

- Example using skin sensitization data
- Hexagons are KEs, rectangles are assays that align with each KE and can inform on a chemical's activity (squares).
- Overlay query results on AOPN to see where there is concordance or difference between assays and chemicals.
- Red compound (5-methyl-2,3-hexanedione, a sensitizer) is always active (up) while the dark blue compound (glycerol, a nonsensitizer) is always inactive (down). Chemicals represented by cyan (linalool) and green (benzoyl peroxide) have mixed responses.
- Easy to identify assays (example DPRA) that give consistent results with the AO of human potency across all chemicals.



How do components relate to overall toxicity?

- Example considering a formulation containing propiconazole, tebuconazole, and imidacloprid
- Each color represents results from a different active ingredient in the formulation (EPA Category III for acute systemic toxicity). The formulation contains propiconazole (blue), tebuconazole (green), and imidacloprid (no data), the formulation data is also included in red; height of the colored bars indicate magnitude of the effect.
- Overlaying available ICE data on an AOPN can provide insight as to the relevance of the AOPN for the formulation, the active ingredients, and possible routes of toxicity.
- Available data indicate no activity for multiple KE.



Acknowledgements

This project was funded in whole or in part with federal funds from the National Institute of Environmental Health Sciences, National Institutes of Health, Department of Health and Human Services, under Contract No. HHSN273201500010C.

The views expressed above do not necessarily represent the official positions of any federal agency. Since the poster was written as part of the official duties of the authors, it can be freely copied.

Contact Us

Access ICE

ICE is maintained by the National Toxicology Program Interagency Center for the Evaluation of Alternative Toxicological Methods (NICEATM).

Want to explore ICE? Scan the QR code to the right or go to the ICE landing page at

<https://ice.ntp.niehs.nih.gov>



Subscribe to the NICEATM News Email List

To get announcements of NICEATM activities, visit the NIH mailing list page for NICEATM News at <https://list.nih.gov/cgi-bin/wa.exe?SUBED1=niceatm-l&A=1> and click “Subscribe”

Read More About ICE!

Bell SM, Phillips J, Sedykh A, Tandon A, Sprankle C, Morefield SQ, Shapiro A, Allen D, Shah R, Maull EA, Casey WM, Kleinstreuer NC. 2017. An Integrated Chemical Environment to support 21st century toxicology. *Environmental Health Perspectives*. DOI 10.1289/EHP1759